← All trials
NCT04874038
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 22, 2021
- Primary completion
- Jan 1, 2024
- Completion date
- Dec 1, 2024
- First posted
- May 5, 2021
- Last posted
- Oct 11, 2021
- Enrollment
- 1150
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of TorontoLead sponsor
- University of TorontoOverall official - principal investigator
- Canadian Institutes of Health Research (CIHR)Collaborator
- McMaster UniversityOverall official - principal investigator
- Kingston Health Sciences CentreOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.